What's in Oncopeptides AB's pipeline?

Oncopeptides AB has 2 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Oncopeptides AB's portfolio?

Top competitors by shared drug class: , Apotex, Avet Lifesciences, Baxter, Eisai.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/oncopeptides-ab.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Oncopeptides AB — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oncopeptides AB pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Pepaxto	MELPHALAN FLUFENAMIDE	marketed	Alkylating Drug		Oncology	2021-01-01

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2032-04-25 — Pepaxto · 10285946 · US
2032-04-25 — Pepaxto · 10322182 · US
2032-04-25 — Pepaxto · 10543274 · US
2032-04-25 — Pepaxto · 10869928 · US
2032-04-25 — Pepaxto · 11344622 · US

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Apotex · 1 shared drug class
Avet Lifesciences · 1 shared drug class
Baxter · 1 shared drug class
Eisai · 1 shared drug class
Leadiant Biosci Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Oncopeptides AB:

Cite this brief

Drug Landscape (2026). Oncopeptides AB — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/oncopeptides-ab. Accessed 2026-06-10.